FDA issued Complete Response Letter Capricor plans to resubmit its BLA to include data from the ongoing Phase 3 HOPE-3 trial ...

Capricor Therapeutics said on Friday the U.S. Food and Drug Administration has declined to approve its cell therapy ...

Capricor Therapeutics shares plummeted in premarket trading Friday after the U.S. Food and Drug Administration turned away the biotechnology company's bid for approval of Deramiocel, its lead ...

Capricor Therapeutics (NASDAQ:CAPR) shares fell Friday after the company announced it received a complete response letter from the U.S. Food and Drug Administration for its Biologics License ...

Capricor, which was seeking approval of Deramiocel for the treatment of cardiomyopathy associated with DMD, said the FDA issued a so-called complete response letter, indicating the agency won't ...

Investing.com -- Capricor Therapeutics (NASDAQ: CAPR) stock plunged 53% after the company received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) rejecting its ...

Capricor Company Contact: AJ Bergmann, Chief Financial Officer abergmann@capricor.com 858.727.1755. The articles, information, and content displayed on this webpage may include materials ...

Capricor's lead asset, deramiocel, targets DMD-related cardiomyopathy and faces key FDA milestones (ADCOM, PDUFA) in 2025. A strong cash position and partnership with Nippon Shinyaku provide ...

Capricor Therapeutics announced positive results from the four-year HOPE-2 Open-Label Extension study for their lead cell therapy candidate, Deramiocel, aimed at treating Duchenne Muscular ...

Capricor Company Contact: AJ Bergmann, Chief Financial Officer abergmann@capricor.com 858.727.1755. This article was originally published on Quiver News, read the full story.

Capricor (CAPR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...